Background/Introduction: Type 4a myocardial infarction (MI) occurs when myocardial injury is combined with either symptoms suggestive of myocardial ischaemia, new left bundle branch block, angiographic loss of patency of a major artery or imaging suggestive of new loss of myocardium. Myocardial injury is defined as a rise of >5 x 99th upper reference limit (URL) of 14 ng/l (i.e. >70 ng/l) for highly sensitive troponin T (hsTnT) at 6 h if hsTnT was normal at baseline or >20% rise from 0 to 6 h if hsTnT was >14 ng/l at baseline. Aim: To assess the prognostic value of biomarkers of myocardial injury following elective percutaneous coronary intervention (PCI). Design: A cohort of 209 patients were included of whom 144 (68.9%) were male, mean age was 68.8 years, 28 (13.4%) were smokers, 31 (14.8%) were diabetic, 199 (95.2%) had hypercholesterolaemia and 138 (66.0%) had hypertension. Methods: We evaluated hsTnT, heart-type fatty acid-binding protein (H-FABP), troponin I (TnI), creatine kinase MB type (CKMB), myoglobin, glycogen phosphorylase BB (GPBB) and carbonic anhydrase III (CA III) at 0, 4, 6 and 24 h following elective PCI. Patients were followed up at 1 year to assess for major adverse clinical events (MACE). Results: Myocardial injury was observed in 37 (17.7%) patients. Median hsTnT/H-FABP at 4 h were most predictive. MACE was noted in 6 (2.9%) patients, 3 had type 4a MI post PCI, P ¼ 0.036. Discussion/Conclusions: Median 4 h hsTnT/H-FABP were most predictive of myocardial injury following PCI. H-FABP and hsTnT were predictive of MACE.
Introduction
Myocardial injury/type 4a MI Percutaneous coronary intervention (PCI) has in the last 20 years revolutionized the treatment of chronic angina pectoris and acute coronary syndrome (ACS), improving prognosis and symptoms. Myocardial infarction associated with PCI is termed type 4a myocardial infarction when myocardial injury secondary to necrosis is combined with either symptoms suggestive of myocardial ischaemia, new left bundle branch block, angiographic loss of patency of a major artery or imaging suggestive of new loss of myocardium. 1 
Definition of myocardial injury
This is defined as a rise of >5 x 99th upper reference limit (URL) of cardiac troponin if troponin is normal at baseline or >20% rise if troponin is elevated at baseline. 1 The URL for highly sensitive troponin T (hsTnT) is 14 ng/l. Therefore, myocardial injury as a consequence of necrosis would result in a level of >70 ng/l if normal at baseline or a 20% rise if >14 ng/l at baseline. Little is known on the prognostic valve of biomarkers following elective PCI.
Prognostic significance
Debate has surrounded the significance of myocardial injury and type 4a MI. Various studies have shown that patients' with post procedure CKMB elevation have worse short and long-term prognosis compared with patients without biomarker elevation. [2] [3] [4] A meta-analysis of 6 trials showed a stepwise increase in mortality with increasing levels of CKMB post PCI. 5 However, the significance of this has been questioned as modest CKMB rises of less than x5 URL may not be associated with adverse prognosis but may simply identify high risk patients that can be identified angiographically or on clinical correlation. 6 In addition, many of these clinical trials predated modern stent technology, widespread use of glycoprotein IIb/ IIIa inhibitors and clopidogrel which have reduced complication rates. [7] [8] [9] Troponin, a more sensitive marker of myocardial necrosis is frequently elevated post PCI. The prognostic significance of this has been debated with trials reporting both adverse prognostic impact 10, 11 and the absence of prognostic impact after PCI.
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Elective PCI Day case PCI is of increasing interest as it has been shown to be safe and cost saving. 14, 15 Patients are monitored for 6 h post PCI after which time complications have been shown to be rare.
14 Difficulty exists around assessing biomarkers 24 h post PCI therefore an ideal biomarker would reflect myocardial damage very soon after PCI thus permitting measurement at 4-6 h guiding decision making.
Other biomarkers have shown promise in the diagnosis of ACS and may be of use in type 4a MI. These include heart-type fatty acid-binding protein (H-FABP) which has been associated with increased cardiovascular events. 16, 17 In addition, glycogen phosphorylase BB (GPBB), myoglobin and carbonic anhydrase III (CA III) have been used. 16, 18, 19 The release kinetics of these biomarkers is such that they rise soon after myocardial necrosis (<6 h) and return to near baseline within 24-36 h. This has the potential to make them useful markers of type 4a MI and facilitate safe discharge at 6 h if levels are normal.
More recently, hsTnT has been shown to be useful in the early diagnosis of ACS compared with previous generations of troponin. 20, 21 The implication of small rises of hsTnT post PCI is unclear and may reflect minor myocardial injury rather than an actual complication. This study assesses biomarker release kinetics up to 6 h post elective PCI to aid identification of myocardial injury and determine any association of procedural myocardial injury with adverse clinical outcomes.
Materials and methods

Study design and patient selection
A prospective cohort study in a single cardiology centre in the United Kingdom was carried out. Regional ethical committee approval in addition to research and development committee approval was granted. The trial was registered with an International Standardised Randomized Control Trial Number (ISRCTN52922229). The study was compliant with the Declaration of Helsinki.
Recruitment
We enrolled 241 patients of whom 32 were excluded due to withdrawal of consent or PCI being cancelled after angiography. Written consent was obtained from all patients. Patient demographics were recorded. Patients with recent myocardial infarction, heart failure hospitalization or stroke (within 6 weeks of recruitment) were excluded.
Laboratory analysis
We prospectively evaluated hsTnT, H-FABP, TnI, CKMB, myoglobin, GPBB and CA III at 0 (before angiography), 4, 6 and 24 h following elective PCI. Samples were centrifuged within 30 min of sampling at 3800 rpm for 5 min. Following centrifuge, the supernatant fluid was transferred into anonymously coded cryotubes and immediately frozen at -80 degrees Celsius. Directly prior to biomarker measurement and biochip analysis, samples were thawed in one freeze-thaw cycle (Randox Laboratories LTD, Crumlin, Northern Ireland). All analysis was performed in one core laboratory by independent and blinded operators. All patient time-points were measured within the same biochip run. An 'Evidence Investigator' analyser (Randox Laboratories LTD) with biochips (Randox Laboratories LTD) were used for analysis.
Primary endpoint
The primary endpoint was myocardial injury at 6 h defined as a rise of >5 x 99th upper reference limit (URL) of 14 ng/l (i.e. rise of >70 ng/l) at 6 h if hsTnT was normal at baseline or >20% from 0 to 6 h if hsTnT was >14 ng/l at baseline. Biomarkers were assessed at 4 h to assess predictive performance of earlier diagnosis of myocardial injury.
Secondary endpoint
Patients were assessed for secondary endpoints of major adverse clinical events (MACE) at 1 year which included acute MI, heart failure hospitalization, stroke, target vessel revascularization and death. Biomarkers were assessed at 6 h for predicting 1 year MACE.
Statistical analysis
Categorical variables are presented as total number (n) and percentage (%). Continuous variables are presented as mean/standard deviation (SD) if parametric and median/interquartile range (IQR) if non parametric. Shapiro-Wilk test was used to assess for normality. Categorical variables were compared using Chi squared test. Continuous variables were compared using independent student t-test when parametric (normally distributed) and Mann-Whitney U test when non parametric (not normally distributed). Statistical significance was considered if P < 0.05. Receiver Operating Characteristic (ROC) analysis using Area Under Curve (AUC) was used to assess the diagnostic accuracy of biomarkers by displaying true-positive rates (sensitivity) vs. false-positive rates (1-specificity). Data was analysed using SPSS version 22.
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Results
Demographics
A cohort of 209 patients was included in analysis of whom 144 (68.9%) were male, mean age was 68.8 years. Myocardial injury was observed in 37 (17.7%) patients. Comparing the 37 myocardial injury patients with the 172 non-myocardial injury patients, mean age was 72.7 years vs. 68.1 years (P ¼ 0.015). Demographics of the patient cohort are shown in Table 1 which also highlights the risk factors between both groups showing no statistical difference (P > 0.05) with the exception of age. Table 2 highlights a summary of biomarker results in both groups at baseline prior to PCI. This shows that even at baseline, patients who would develop myocardial injury post PCI has a significantly elevated hsTnT (16.8 ng/dl vs. 7.8 ng/l, AUC 0.77, P < 0.001) and H-FABP (2.75 ng/ml vs. 1.85 ng/ml, AUC 0.76, P < 0.001). Of the 37 myocardial injury patients, 26 (70.2%) patients had normal baseline hsTnT with >5 URL rise at 6 h and 11 (29.8%) had a baseline > 14 ng/l with >20% rise (as per type 4a MI criteria). Myocardial injury patients with a baseline hsTnT >14 ng/dl had significantly raised baseline creatinine results consistent with chronic kidney disease (mean creatinine 153 lmol/l, range 113-382 lmol/l) in comparison to nonmyocardial patients (mean creatinine 99 lmol/l, range 62-123 lmol/l). This was felt to explain the raised baseline hsTnT in this cohort of stable out-patients. 
Baseline results
hsTnT results
At 4 h median hsTnT was 69.15 ng/l in the myocardial injury group vs. 12.18 ng/l in the non-myocardial injury group, AUC 0.95, P < 0.001, Table 3 , Figure 1 . At 6 h median hsTnT was 90.24 ng/l vs. 14.43 ng/l in the myocardial injury/non myocardial injury groups respectively, P ¼ <0.001, Figure 1 . Table 4 also demonstrates the delta change in biomarkers from 0-6 h in the myocardial injury and non-myocardial injury patients. Myocardial injury patients had particularly significant rises in hsTnT and H-FABP.
H-FABP results
Median H-FABP was also predictive of myocardial injury at baseline, 2.75 ng/ml vs. 1.85 ng/ml, AUC 0.76, P < 0.001, Table 2 , Figure  2 . H-FABP was significantly elevated at 4 h and was predictive of myocardial injury with levels of 6.23 ng/ml vs. 2.05 ng/ml in the myocardial injury/non myocardial injury groups, respectively, P ¼ <0.001, AUC 0.91, Table 3 , Figure 2 .
Other biomarkers
Results for TnI, CKMB, myoglobin, GPBB and CA III are shown in Table 3 . Although they were not as predictive as H-FABP, CKMB and myoglobin showed a modest correlation to myocardial injury. Levels of GBPP and CAIII were not predictive.
Major adverse clinical events (MACE)
MACE was noted in 6 (2.9%) patients (three MI, two death and one stroke). Three (50%) of these patients were in the myocardial injury, P ¼ 0.036. The mean 6 h hsTnT in the MACE group was 106 ng/l (range 8 ng/l-389 ng/l). hsTnT, highly sensitive troponin T; H-FABP, heart-type fatty acid-binding protein; TnI, troponin I; CKMB, creatine kinase MB; GPBB, glycogen phosphorylase; CA III, carbonic anhydrase III; SD, standard deviation; 95% CI, 95% confidence interval; AUC, area under curve. 
Discussion
Myocardial injury
The only clinical risk factor statistically associated with development of myocardial injury was older age. At 6 h, hsTnT was significantly higher in the myocardial injury group. This was expected as troponin elevation forms part of the diagnosis of myocardial injury/type 4a MI. Of all biomarkers, absolute values of hsTnT and H-FABP at 4 h and delta change from 0-6 h performed best and predicted myocardial injury post PCI. Even at baseline (prior to PCI), hsTnT and H-FABP was associated with myocardial injury. This was followed by CKMB and myoglobin. TnI did not appear to rise by 4 h in either group (0.18 is the lowest detectable level of TnI on the biochip used), however Table 4 demonstrates how myocardial injury patients do appear to have a rise from 0-6 h, likely as a result of TnI rising later than other biomarkers.
Neither absolute values at 6 h nor delta change from 0-6 h of GPBB or CA III were predictive of myocardial injury.
Mace
In total, 6 (2.9%) patients developed MACE at 1 year. Absolute values of hsTnT at 6 h in addition to absolute 6 h and delta change from 0-6 h in H-FABP were predictive of MACE at 1 year. Of the 6 patients who developed MACE, half developed myocardial injury at index PCI. Therefore, 3 (8.1%) of the 37 myocardial injury patients developed an adverse outcome compared with 3 (1.7%) of the 172 non myocardial injury patients at 1 year, P ¼ 0.036. This highlights a correlation of biomarker rises and adverse events.
Limitations
This was performed in a single centre and only a modest number developed myocardial injury and MACE. Time-points were limited to an extent as patients were stable out-patients routinely discharged at 6 h. The definition of myocardial injury and type 4a MI is based on troponin.
There are notably strengths to this study. Most previously published papers in this field have small numbers and few time-points. Each of our 209 patients had 6 biomarkers taken at each of four time-points. This allowed accurate time course release data from each biomarker in both myocardial injury/ non myocardial injury and MACE/non MACE patients. Multiple biomarkers were analysed from the same plasma/serum samples providing strong internal validity to our data. The remaining biomarkers did not predict MACE (absolute or delta rise) with the exception of delta rise in CA III.
Conclusions
Myocardial injury post PCI is common, however, MACE at 1 year is relatively rare, likely as a consequence of improved stent technology and pharmacology. Median 4 h hsTnT and H-FABP was most predictive of myocardial injury following elective PCI, followed by CKMB and myoglobin. H-FABP and hsTnT at 6 h were independently associated with MACE at 1 year.
Impact on daily practice
H-FABP and hsTnT at 4 h is a good predictor of myocardial injury. Both hsTnT and H-FABP at 6 h are predictors of MACE and therefore patients with normal levels of biomarkers post day case PCI would be deemed very low risk for adverse events. hsTnT, highly sensitive troponin T; H-FABP, heart-type fatty acid-binding protein; TnI, troponin I; CKMB, creatine kinase MB; GPBB, glycogen phosphorylase; CA III, carbonic anhydrase III; SD, standard deviation; 95% CI, 95% confidence interval; AUC, area under curve.
